Ixinity

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Ixinity
Generic name
COAGULATION FACTOR IX (RECOMBINANT)
Manufacturer
Medexus Pharma, Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
26bc221d-c9bc-4aba-92f3-6c21acaaf194
SPL ID
5e2b1242-2977-463b-ac2c-f89dadfba407
Version
8
Effective date
2024-04-03
Source export date
2026-11-13
Source partition
13
Source file
https://download.open.fda.gov/drug/label/drug-label-0013-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/59f616a891fdb32b85469f3498f080490e31c92c33c42932fcf32980bd661882/drug-label-0013-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 18:12:38

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis has occurred. Should symptoms occur, discontinue IXINITY and administer appropriate treatment. Patients may also develop hypersensitivity to hamster (CHO) protein, which is present in trace amounts in the product ( 5.1 ) Development of neutralizing antibodies (inhibitors) to IXINITY may occur. If expected factor IX activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor IX inhibitor concentration ( 5.2 ) Nephrotic syndrome has been reported following immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitors ( 5.3 ) Thromboembolism has occurred with IXINITY use ( 5.4 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, has occurred with IXINITY. Signs of allergic reactions, which can progress to anaphylaxis, include urticaria, angioedema, chest or throat tightness, hypotension, lethargy, nausea, vomiting, dysphagia, paresthesia, restlessness, wheezing and dyspnea. Immediately discontinue administration and initiate appropriate treatment if allergic or anaphylactic-type reactions occur. In case of severe allergic reactions, consider alternative hemostatic measures. There are literature reports of allergic reactions occurring in close temporal association with the development of factor IX inhibitors. IXINITY contains trace amounts of Chinese hamster ovary (CHO) proteins. Patients treated with this product may develop hypersensitivity to CHO proteins. 5.2 Neutralizing Antibodies Development of neutralizing antibodies (inhibitors) to IXINITY may occur. If expected factor IX activity plasma levels are not attained, or if bleeding is not controlled as expected with the calculated dose, perform an assay that measures factor IX inhibitor concentration [see Warnings and Precautions (5.5) ]. Patients with factor IX inhibitors are at an increased risk of severe hypersensitivity reactions or anaphylaxis if re-exposed to IXINITY. 5.3 Nephrotic Syndrome Nephrotic syndrome may occur with IXINITY. Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors and a history of allergic reactions. 5.4 Thromboembolism Thromboembolism has occurred with IXINITY use. One thrombotic event of deep vein thrombosis was reported in an adult female over 45 years of age from post-marketing experience. Because of the potential risk for thromboembolism with the use of factor IX products, monitor for early signs of thromboembolism and consumptive coagulopathy when administering IXINITY to patients with liver disease, fibrinolysis, peri-operative status, or risk for thromboembolic events or disseminated intravascular coagulation. 5.5 Monitoring Laboratory Tests Monitor patients for factor IX activity levels with the one-stage clotting assay to confirm that adequate factor IX levels have been achieved and maintained, when clinically indicated. Factor IX results can be affected by the type of aPTT reagent used [see Dosage and Administration (2.1) ]. Monitor patients for the development of inhibitors if expected factor IX activity plasma levels are not attained, or if bleeding is not controlled with the recommended dose of IXINITY. Assays used to determine if factor IX inhibitor is present should be titered in Bethesda Units (BUs).

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reaction (> 2%) reported in clinical trials was headache. The most common adverse reaction observed in > 2% of patients in clinical trials was headache ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Medexus Pharma, Inc. at 1-844-859-6675 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 15 adverse reactions were reported following IXINITY administration among 7 of the 98 subjects who received at least one dose of IXINITY in trials of previously treated patients (PTPs), which included 11 subjects 12 - 18 years of age and 21 subjects < 12 years of age. A total of 12,952 infusions of IXINITY were administered to the 98 subjects. The adverse reactions that were assessed as probably or possibly related to study drug are provided in the table below. Table 3 Summary of Adverse Reactions MedDRA Standard System Organ Class Adverse Reaction Number of Events Number of Subjects (n = 98) (%) Congenital, familial and genetic disorders Hemophilia (i.e., lack of efficacy) 1 1 (1.0%) General disorders and administration site conditions Asthenia 1 1 (1.0%) Injection site discomfort 1 1 (1.0%) Immune System Disorders Hypersensitivity 1 1 (1.0%) Infections and infestations Influenza 1 1 (1.0%) Nervous system disorders Headache 5 2 (2.0%) Dysgeusia 1 1 (1.0%) Lethargy 1 1 (1.0%) Psychiatric disorders Apathy 1 1 (1.0%) Depression 1 1 (1.0%) Skin and subcutaneous tissue disorders Rash pruritic 1 1 (1.0%) 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of IXINITY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders: Anaphylaxis Vascular Disorders: Deep vein thrombosis The following class adverse reactions have been seen with another recombinant factor IX: inadequate factor IX recovery, inhibitor development, angioedema, hypotension, and thrombosis.

adverse reactions table

<table width="700" styleCode="Noautorules" ID="t_03"><caption>Table 3 Summary of Adverse Reactions</caption><col width="40%"/><col width="25%"/><col width="10%"/><col width="25%"/><tbody><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold">MedDRA Standard System Organ Class</content></td><td styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold">Adverse Reaction </content></td><td styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold">Number of Events</content></td><td styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold">Number of Subjects (n = 98) (%)</content></td></tr><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule">Congenital, familial and genetic disorders</td><td styleCode="Toprule Botrule Lrule Rrule">Hemophilia (i.e., lack of efficacy)</td><td styleCode="Toprule Botrule Lrule Rrule">1</td><td styleCode="Toprule Botrule Lrule Rrule">1 (1.0%)</td></tr><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule" rowspan="2">General disorders and administration site conditions</td><td styleCode="Toprule Botrule Lrule Rrule">Asthenia</td><td styleCode="Toprule Botrule Lrule Rrule">1</td><td styleCode="Toprule Botrule Lrule Rrule">1 (1.0%)</td></tr><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule">Injection site discomfort</td><td styleCode="Toprule Botrule Lrule Rrule">1</td><td styleCode="Toprule Botrule Lrule Rrule">1 (1.0%)</td></tr><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule">Immune System Disorders</td><td styleCode="Toprule Botrule Lrule Rrule">Hypersensitivity</td><td styleCode="Toprule Botrule Lrule Rrule">1</td><td styleCode="Toprule Botrule Lrule Rrule">1 (1.0%)</td></tr><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule">Infections and infestations</td><td styleCode="Toprule Botrule Lrule Rrule">Influenza</td><td styleCode="Toprule Botrule Lrule Rrule">1</td><td styleCode="Toprule Botrule Lrule Rrule">1 (1.0%)</td></tr><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule" rowspan="3">Nervous system disorders</td><td styleCode="Toprule Botrule Lrule Rrule">Headache</td><td styleCode="Toprule Botrule Lrule Rrule">5</td><td styleCode="Toprule Botrule Lrule Rrule">2 (2.0%)</td></tr><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule">Dysgeusia</td><td styleCode="Toprule Botrule Lrule Rrule">1</td><td styleCode="Toprule Botrule Lrule Rrule">1 (1.0%)</td></tr><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule">Lethargy</td><td styleCode="Toprule Botrule Lrule Rrule">1</td><td styleCode="Toprule Botrule Lrule Rrule">1 (1.0%)</td></tr><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule" rowspan="2">Psychiatric disorders</td><td styleCode="Toprule Botrule Lrule Rrule">Apathy</td><td styleCode="Toprule Botrule Lrule Rrule">1</td><td styleCode="Toprule Botrule Lrule Rrule">1 (1.0%)</td></tr><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule">Depression</td><td styleCode="Toprule Botrule Lrule Rrule">1</td><td styleCode="Toprule Botrule Lrule Rrule">1 (1.0%)</td></tr><tr valign="top"><td styleCode="Toprule Botrule Lrule Rrule">Skin and subcutaneous tissue disorders</td><td styleCode="Toprule Botrule Lrule Rrule">Rash pruritic</td><td styleCode="Toprule Botrule Lrule Rrule">1</td><td styleCode="Toprule Botrule Lrule Rrule">1 (1.0%)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.